Description
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research[1][2].–Applications-Metabolism-sugar/lipid metabolism-Formula-N/A-Citation–References-[1]Liu F, et al. Downregulation of CPT2 promotes proliferation and inhibits apoptosis through p53 pathway in colorectal cancer. Cell Signal. 2022 Apr;92:110267. |[2]Joshi PR, et al. Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules. 2020 Apr 13;25(8):1784. -CASNumber-1670277-66-3-MolecularWeight-N/A-Compound Purity–SMILES-[CPT2]-Research_Area-Cancer; Metabolic Disease-Solubility-10 mM in DMSO-Target-Apoptosis;MDM-2/p53-Isoform–Pathway-Apoptosis-MCE Product type-Enzyme
